Cargando…

S236. QUALITY OF LIFE AND ASSOCIATION WITH SYMPTOMS IN PATIENTS WITH SCHIZOPHRENIA SIX YEARS AFTER FIRST EPISODE PSYCHOSES

BACKGROUND: Quality of Life in patients with schizophrenia is an important part of successful treatment outcome. Our previous results showed, that despite symptomatic improvement after six weeks of antipsychotic treatment, the overall Quality of Life was not improved. The aim of the present study is...

Descripción completa

Detalles Bibliográficos
Autores principales:	Andersen, Gitte, Schaebel, Helle, Gehr, Johannes, Glenthoj, Birte, Nielsen, Mette Ødegaard
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2020
Materias:	Poster Session I
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7234023/ http://dx.doi.org/10.1093/schbul/sbaa031.302

Ejemplares similares

S250. RELATION BETWEEN PSYCHOPATHOLOGY AND QUALITY OF LIFE IN SCHIZOPHRENIA PATIENTS BEFORE AND AFTER FIRST ANTIPSYCHOTIC TREATMENT
por: Andersen, Gitte, et al.
Publicado: (2018)

Differential Effects of Aripiprazole and Amisulpride on Negative and Cognitive Symptoms in Patients With First-Episode Psychoses
por: Nielsen, Mette Ødegaard, et al.
Publicado: (2022)

S215. FRONTO-TEMPORAL CEREBRAL BLOOD FLOW AND COGNITIVE FUNCTIONING IN PATIENTS WITH FIRST EPISODE PSYCHOSES TREATED WITH ARIPIPRAZOLE: PRELIMINARY FINDINGS
por: Peitl, Vjekoslav, et al.
Publicado: (2020)

S80. CHILDHOOD TRAUMA AND SOCIAL COGNITION IN DELUSIONAL PSYCHOSES
por: Díaz-Caneja, Covadonga, et al.
Publicado: (2020)

S133. DIAGNOSED SPEECH, SCHOLASTIC AND MOTOR DISORDERS AS PREDICTORS FOR NON-AFFECTIVE PSYCHOSES
por: Gyllenberg, David, et al.
Publicado: (2020)

F236. CLONIDINE NORMALIZES MMN IN SCHIZOPHRENIA PATIENTS ON STABLE MEDICATION
por: Kruiper, Caitlyn, et al.
Publicado: (2018)

Alterations of Intrinsic Connectivity Networks in Antipsychotic-Naïve First-Episode Schizophrenia
por: Anhøj, Simon, et al.
Publicado: (2018)

M148. NORMALIZATION IN REWARD PROCESSING DURING INITIAL TREATMENT MAY PREDICT LONG-TERM CLINICAL OUTCOME IN ANTIPSYCHOTIC NAïVE SCHIZOPHRENIA PATIENTS
por: Nielsen, Mette, et al.
Publicado: (2020)

Reward Processing as an Indicator of Vulnerability or Compensatory Resilience in Psychoses? Results From a Twin Study
por: Nielsen, Mette Ødegaard, et al.
Publicado: (2022)

S246. PSYCHOMETRIC PROPERTIES OF THE DANISH VERSION OF BNSS (BNSS-DA)
por: Gehr, Johannes, et al.
Publicado: (2018)

S12. A MACHINE LEARNING FRAMEWORK FOR ROBUST AND RELIABLE PREDICTION OF SHORT- AND LONG-TERM CLINICAL RESPONSE IN INITIALLY ANTIPSYCHOTIC-NAïVE SCHIZOPHRENIA PATIENTS BASED ON MULTIMODAL NEUROPSYCHIATRIC DATA
por: Ambrosen, Karen S, et al.
Publicado: (2020)

S244. RELIABILITY OF CORE SCHIZOPHRENIA SYMPTOMS RATINGS USING THE SIX-ITEM POSITIVE AND NEGATIVE SYNDROME SCALE (PANSS-6) PERFORMED BY MEDICAL STUDENTS
por: Hansen, Johanna, et al.
Publicado: (2020)

S171. EFFECT OF DAOA GENETIC VARIATION ON WHITE MATTER ALTERATION IN CORPUS CALLOSUM IN PATIENTS WITH FIRST-EPISODE SCHIZOPHRENIA
por: Su, Wenjun, et al.
Publicado: (2020)

S72. MCCB COGNITIVE PROFILE IN CHINESE FIRST EPISODE SCHIZOPHRENIA PATIENTS AND SUBJECTS AT CLINICAL HIGH RISK FOR PSYCHOSIS
por: Lei, Zhao, et al.
Publicado: (2020)

S100. INCORRECT DIAGNOSIS OF FIRST EPISODE SCHIZOPHRENIA: IMPACT OF ANXIETY AND THOUGHT DISORDER, AND THE VALUE OF A CONSULTATION CLINIC
Publicado: (2020)

S51. ANALYSIS OF SOCIAL COGNITION AS A PREDICTIVE FACTOR OF PSYCHOSIS IN 22Q11 DELETION SYNDROME (DS). DATA FROM THE MULTICENTER STUDY OF THE ITALIAN NETWORK FOR RESEARCH ON PSYCHOSES
por: Accinni, Tommaso, et al.
Publicado: (2020)

S6. SLEEP ENDOPHENOTYPES OF SCHIZOPHRENIA: A HIGH-DENSITY EEG STUDY IN DRUG-NAïVE, FIRST EPISODE PSYCHOSIS PATIENTS
por: Castelnovo, Anna, et al.
Publicado: (2020)

S201. HIPPOCAMPAL SUBFIELD VOLUMES AND CHANGE IN BODY MASS OVER 12 MONTHS OF TREATMENT IN FIRST-EPISODE SCHIZOPHRENIA SPECTRUM DISORDERS
por: Du Plessis, Stéfan, et al.
Publicado: (2020)

T10. BIOMARKERS IN TREATMENT-RESISTANT SCHIZOPHRENIA; THE BITS STUDY (A STUDY PROTOCOL)
por: Hilker, Rikke, et al.
Publicado: (2020)

S209. DRUG-NAïVE FIRST-EPISODE SCHIZOPHRENIA SPECTRUM DISORDERS: PHARMACOLOGICAL TREATMENT PRACTICES IN INPATIENT UNITS IN HUNAN PROVINCE, CHINA
por: Zhu, Mengran, et al.
Publicado: (2020)

S115. EVALUATION OF THE CLINICAL UTILITY OF SYMPTOM DIMENSIONS ON LONG-TERM CLINICAL AND FUNCTIONAL OUTCOMES IN FIRST EPISODE PSYCHOSIS
por: Bor, Ege, et al.
Publicado: (2020)

S196. TRANSCRANIAL MAGNETIC STIMULATION IN SCHIZOPHRENIA WITH PROMINENT NEGATIVE SYMPTOMS- A REVIEW OF THE LITERATURE
por: Vasiliu, Octavian
Publicado: (2020)

S55. PRAGMATIC INFERENCES IN SCHIZOPHRENIA: RELATIONSHIP WITH SYMPTOM DOMAINS, THEORY OF MIND AND NEUROCOGNITIVE FUNCTIONS
por: Yalincetin, Berna, et al.
Publicado: (2020)

Striatal Volume Increase After Six Weeks of Selective Dopamine D(2/3) Receptor Blockade in First-Episode, Antipsychotic-Naïve Schizophrenia Patients
por: Andersen, Helle G., et al.
Publicado: (2020)

S101. DIFFERENTIATING NON-AFFECTIVE ACUTE REMITTING PSYCHOSIS (NARP) FROM SCHIZOPHRENIA IN FIRST-EPISODE PSYCHOSIS: FINDINGS FROM A 3-YEAR LONGITUDINAL STUDY IN THE PAFIP COHORT
por: López-Díaz, Álvaro, et al.
Publicado: (2020)

S36. TREATING NEGATIVE SYMPTOMS OF SCHIZOPHRENIA WITH A MOTIVE-SPECIFIC INTERVENTION: A RANDOMIZED BRIEF INTERVENTION TRIAL
por: Horisberger, Rahel, et al.
Publicado: (2020)

S193. EFFICACY AND SAFETY OF TRANSCRANIAL DIRECT CURRENT STIMULATION FOR TREATING NEGATIVE SYMPTOMS IN SCHIZOPHRENIA: THE FOLLOW-UP PHASE
por: Valiengo, Leandro, et al.
Publicado: (2020)

S26. PSYCHOSIS-SPECTRUM SYMPTOMS AMONG ADOLESCENTS PSYCHIATRICALLY HOSPITALIZED FOR ACUTE SAFETY CONCERNS ARE LINKED TO READMISSION WITHIN SIX MONTHS OF DISCHARGE
por: Thompson, Elizabeth, et al.
Publicado: (2020)

Striatal D(2/3) Binding Potential Values in Drug-Naïve First-Episode Schizophrenia Patients Correlate With Treatment Outcome
por: Wulff, Sanne, et al.
Publicado: (2015)

S166. EFFECTIVE CONNECTIVITY OF FRONTOSTRIATAL SYSTEMS IN FIRST-EPISODE PSYCHOSIS
por: Sabaroedin, Kristina, et al.
Publicado: (2020)

S150. EMOTIONAL BEHAVIOUR IN HIGH-RISK AND FIRST-EPISODE PSYCHOSIS
por: Falkenberg, Irina, et al.
Publicado: (2020)

O6.3. ASSOCIATIONS BETWEEN COGNITIVE FUNCTION AND CORTICAL LEVELS OF GLUTAMATE AND GABA IN ANTIPSYCHOTIC-NAïVE PATIENTS WITH SCHIZOPHRENIA OR PSYCHOSIS
por: Bojesen, Kirsten, et al.
Publicado: (2020)

S180. THE SELECTIVE GPR139 AGONIST TAK-041 REVERSES ANHEDONIA AND SOCIAL INTERACTION DEFICITS IN RODENT MODELS RELATED TO NEGATIVE SYMPTOMS IN SCHIZOPHRENIA
por: Schiffer, Hans, et al.
Publicado: (2020)

S34. EFFECTIVENESS OF INDIVIDUAL METACOGNITIVE TRAINING (MCT+) IN FIRST-EPISODE PSYCHOSIS
por: Ochoa, Susana, et al.
Publicado: (2020)

S47. A MULTICENTER STUDY OF COGNITIVE RESERVE IN FIRST-EPISODE PYCHOSIS
por: Amoretti, Silvia, et al.
Publicado: (2020)

S229. THE EFFECT OF FAMILY ENVIRONMENT ON LONGITUDINAL FUNCTIONING IN FIRST PSYCHOTIC EPISODES
por: Verdolini, Norma, et al.
Publicado: (2020)

S221. THE EFFICACY OF LUMATEPERONE 42 MG IN THE TREATMENT OF SCHIZOPHRENIA SYMPTOMS ASSOCIATED WITH SOCIAL FUNCTIONING: POST HOC ANALYSIS OF AN ACUTE PLACEBO- AND ACTIVE-CONTROLLED TRIAL
por: Vanover, Kimberly, et al.
Publicado: (2020)

S10. SCREENING FOR ANTI-NMDAR ANTIBODIES AMONGST PATIENTS WITH FIRST EPISODE PSYCHOSIS
por: Herman, Levente, et al.
Publicado: (2020)

S25. FRAMEWORK FOR THE CHARACTERIZATION OF HIPPOCAMPUS USING RADIOMIC APPROACH IN FIRST-EPISODE PSYCHOSIS
por: Masias, Mireia, et al.
Publicado: (2020)

M131. RETURN TO LABOUR MARKET IN SCHIZOPHRENIA AND OTHER PSYCHOSES – THE NORTHERN FINLAND BIRTH COHORT 1966
por: Majuri, Tuomas, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_3vu1am4mcgpd8b6pikbs10nhe2